153 related articles for article (PubMed ID: 27183094)
1. Melphalan 200 mg/m
Sweiss K; Patel S; Culos K; Oh A; Rondelli D; Patel P
Bone Marrow Transplant; 2016 Oct; 51(10):1337-1341. PubMed ID: 27183094
[TBL] [Abstract][Full Text] [Related]
2. Autologous hematopoietic cell transplantation for multiple myeloma patients with renal insufficiency: a center for international blood and marrow transplant research analysis.
Mahindra A; Hari P; Fraser R; Fei M; Huang J; Berdeja J; Callander N; Costa L; Diaz MA; Freytes C; Gale RP; Girnius S; Holmberg L; Kharfan-Dabaja M; Kumar S; Kyle R; Lazarus H; Lee C; Maiolino A; Moreb J; Nishihori T; Pawarode A; Saad A; Savani BN; Schriber J; William B; Wirk BM; Krishnan A; Nieto Y; D'Souza A
Bone Marrow Transplant; 2017 Dec; 52(12):1616-1622. PubMed ID: 28920949
[TBL] [Abstract][Full Text] [Related]
3. Autologous hematopoietic stem cell transplantation may reverse renal failure in patients with multiple myeloma.
Parikh GC; Amjad AI; Saliba RM; Kazmi SM; Khan ZU; Lahoti A; Hosing C; Mendoza F; Qureshi SR; Weber DM; Wang M; Popat U; Alousi AM; Champlin RE; Giralt SA; Qazilbash MH
Biol Blood Marrow Transplant; 2009 Jul; 15(7):812-6. PubMed ID: 19539212
[TBL] [Abstract][Full Text] [Related]
4. Pretransplant hemoglobin and creatinine clearance correlate with treatment-free survival after autologous stem cell transplantation for multiple myeloma.
Sweiss K; Calip GS; Johnson JJ; Rondelli D; Patel PR
Bone Marrow Transplant; 2019 Dec; 54(12):2081-2087. PubMed ID: 31388085
[TBL] [Abstract][Full Text] [Related]
5. The Impact of Renal Impairment in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation With Melphalan Conditioning.
Ursu SG; Maples S; Williams KJ; Patrus G; Samhouri Y; Fazal S; Mewawalla P; Sadashiv S
J Hematol; 2023 Oct; 12(5):201-207. PubMed ID: 37936977
[TBL] [Abstract][Full Text] [Related]
6. Impact of moderate or severe renal insufficiency on long-term outcomes in patients undergoing drug-eluting stent based coronary intervention.
Zhang RY; Zhu ZB; Zhang Q; Yang ZK; Hu J; Lv AK; Zhang JS; Shen WF
Int J Cardiol; 2009 Jul; 136(1):72-9. PubMed ID: 18653250
[TBL] [Abstract][Full Text] [Related]
7. High dose chemotherapy followed by autologous haemopoietic stem cell transplant in multiple myeloma.
Kumar L; Raju GM; Ganessan K; Shawgi S; Menon H; Wadhwa J; Sharma A; Singh R; Kochupillai V
Natl Med J India; 2003; 16(1):16-21. PubMed ID: 12715951
[TBL] [Abstract][Full Text] [Related]
8. High-Dose Melphalan Plus Thiotepa as Conditioning Regimen before Second Autologous Stem Cell Transplantation for "De Novo" Multiple Myeloma Patients: A Phase II Study.
Musso M; Messina G; Marcacci G; Crescimanno A; Console G; Donnarumma D; Scalone R; Pinto A; Martino M
Biol Blood Marrow Transplant; 2015 Nov; 21(11):1932-8. PubMed ID: 26099830
[TBL] [Abstract][Full Text] [Related]
9. Melphalan dose in myeloma patients ≥65 years of age undergoing high-dose therapy and autologous stem cell transplantation: a multicentric observational registry study.
Ghilardi G; Pabst T; Jeker B; Müller R; Cairoli A; Müller AMS; Bargetzi M; Hitz F; Baldomero H; Heim D; Schmidt A; Rossi D; Ghielmini M; Wannesson L; Lerch E; Samaras P; Schanz U; Passweg JR; Stussi G; Kleber M; Gerber B;
Bone Marrow Transplant; 2019 Jul; 54(7):1029-1037. PubMed ID: 30390061
[TBL] [Abstract][Full Text] [Related]
10. Cyclophosphamide-containing regimen (TCD) is superior to melphalan-containing regimen (MPT) in elderly multiple myeloma patients with renal impairment.
Song MK; Chung JS; Shin HJ; Moon JH; Lee JJ; Yoon SS; Kim JS; Lee JO; Do YR; Lee HS; Park EK;
Ann Hematol; 2012 Jun; 91(6):889-96. PubMed ID: 22237937
[TBL] [Abstract][Full Text] [Related]
11. Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma.
Dimopoulos MA; Cheung MC; Roussel M; Liu T; Gamberi B; Kolb B; Derigs HG; Eom H; Belhadj K; Lenain P; Van der Jagt R; Rigaudeau S; Dib M; Hall R; Jardel H; Jaccard A; Tosikyan A; Karlin L; Bensinger W; Schots R; Leupin N; Chen G; Marek J; Ervin-Haynes A; Facon T
Haematologica; 2016 Mar; 101(3):363-70. PubMed ID: 26659916
[TBL] [Abstract][Full Text] [Related]
12. Autologous transplantation and maintenance therapy in multiple myeloma.
Palumbo A; Cavallo F; Gay F; Di Raimondo F; Ben Yehuda D; Petrucci MT; Pezzatti S; Caravita T; Cerrato C; Ribakovsky E; Genuardi M; Cafro A; Marcatti M; Catalano L; Offidani M; Carella AM; Zamagni E; Patriarca F; Musto P; Evangelista A; Ciccone G; Omedé P; Crippa C; Corradini P; Nagler A; Boccadoro M; Cavo M
N Engl J Med; 2014 Sep; 371(10):895-905. PubMed ID: 25184862
[TBL] [Abstract][Full Text] [Related]
13. Long-term outcome of autologous stem cell transplantation in light chain deposition disease.
Lorenz EC; Gertz MA; Fervenza FC; Dispenzieri A; Lacy MQ; Hayman SR; Gastineau DA; Leung N
Nephrol Dial Transplant; 2008 Jun; 23(6):2052-7. PubMed ID: 18178602
[TBL] [Abstract][Full Text] [Related]
14. Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma.
Gonsalves WI; Leung N; Rajkumar SV; Dispenzieri A; Lacy MQ; Hayman SR; Buadi FK; Dingli D; Kapoor P; Go RS; Lin Y; Russell SJ; Lust JA; Zeldenrust S; Kyle RA; Gertz MA; Kumar SK
Blood Cancer J; 2015 Mar; 5(3):e296. PubMed ID: 25794132
[TBL] [Abstract][Full Text] [Related]
15. Melphalan 200 mg/m2 with blood stem cell support as first-line myeloma therapy: impact of glomerular filtration rate on engraftment, transplantation-related toxicity and survival.
Carlson K
Bone Marrow Transplant; 2005 May; 35(10):985-90. PubMed ID: 15806125
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics, safety, and efficacy of lenalidomide plus dexamethasone in patients with multiple myeloma and renal impairment.
Bridoux F; Chen N; Moreau S; Arnulf B; Moumas E; Abraham J; Desport E; Jaccard A; Fermand JP
Cancer Chemother Pharmacol; 2016 Jul; 78(1):173-82. PubMed ID: 27286995
[TBL] [Abstract][Full Text] [Related]
17. Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma.
Giralt S; Aleman A; Anagnostopoulos A; Weber D; Khouri I; Anderlini P; Molldrem J; Ueno NT; Donato M; Korbling M; Gajewski J; Alexanian R; Champlin R
Bone Marrow Transplant; 2002 Sep; 30(6):367-73. PubMed ID: 12235521
[TBL] [Abstract][Full Text] [Related]
18. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
[TBL] [Abstract][Full Text] [Related]
19. Thalidomide-dexamethasone as induction therapy before autologous stem cell transplantation in patients with newly diagnosed multiple myeloma and renal insufficiency.
Tosi P; Zamagni E; Tacchetti P; Ceccolini M; Perrone G; Brioli A; Pallotti MC; Pantani L; Petrucci A; Baccarani M; Cavo M
Biol Blood Marrow Transplant; 2010 Aug; 16(8):1115-21. PubMed ID: 20197100
[TBL] [Abstract][Full Text] [Related]
20. Lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma and renal impairment.
Zhou DB; Yu L; Du X; Jin J; Cai Z; Chen F; Ke X; Li X; Wu D; Meng F; Ai H; Zhang J; DeMarco D; Chen N; Mei J; Wang J; Hou J
Int J Hematol; 2015 Jun; 101(6):569-77. PubMed ID: 25753225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
